ArticleFrontiers in cardiovascular medicine2025
A LASSO-based predictive nomogram for obstructive coronary artery disease in double zero score patients: validation and cardiovascular education strategies.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Adjunctive Role of Dynamic Systemic Inflammation-Based Biomarkers in Surgical Risk Stratification of First-Episode Primary Spontaneous Pneumothorax.Diagnostics (Basel, Switzerland) · 2026Article
- Burden of subclinical coronary atherosclerosis among asymptomatic adults: the REACH-Rural India Study.The Lancet regional health. Southeast Asia · 2026Article
- Development and validation of a LASSO-selected machine learning prediction pipeline for predicting coronary artery calcification in a health check-up population.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to create a nomogram to predict a double-zero score for obstructive coronary artery disease (CAD) in a hospital-based cohort initially scoring zero. We compared its diagnostic performance with the Framingham risk score (FRS) and models for atherosclerotic cardiovascular disease (ASCVD). Methods: We retrospectively reviewed the clinical features and laboratory profiles of 634 participants with baseline zero coronary artery calcium scores. The target population consisted of individuals with a double-zero score. The primary endpoint was the diagnosis of obstructive CAD, defined as CAD-RADS ≥3 or vulnerable plaque formation on the second cardiac CT. The control group had a double-zero score, with no or less than 50% coronary stenosis. We developed a nomogram using a least absolute shrinkage and selection operation-derived logistic model. We assessed the models' discrimination and calibration abilities using the Hosmer-Lemeshow test. Results: Participants were monitored for an average period of 4.26 ± 2.30 years and were randomly allocated to training and validation sets at a ratio of 2.8:1. The study results indicated that 5.13% (24 of 467) in the training cohort and 4.19% (7 of 167) in the validation cohort developed a double-zero score with obstructive CAD progression. This nomogram incorporated four predictors: "systolic blood pressure," "hypertension," "body fat percentage," and "HbA1c." The nomogram demonstrated superior diagnostic performance compared to the FRS and ASCVD models, with lower values of Akaike information criterion and Bayesian information criterion values. The nomogram's discriminative ability, measured by the area under the curve, was 0.792 in the training cohort and 0.824 in the validation cohort. Conclusions: The validated nomogram provides valuable predictive potential for identifying high-risk subclinical coronary atherosclerosis, thereby supporting personalized primary prevention and education strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.